Drug intelligence / Profile preview

APZ102

Development stage: Preclinical
Lead developer: Foshan Ampze Biopharma

Overview

APZ102 is an innovative anti-tumor drug candidate currently in early development by Foshan Ampze Biopharma (also known as Annpobio). Positioned within the sponsor's oncology pipeline as a novel therapeutic rather than a biosimilar, APZ102 is classified as an innovative drug (创新药) for the treatment of various cancers. Given Foshan Ampze's core technological focus on the research and development of recombinant proteins and antibody-based therapeutics, APZ102 is likely a biologic entity. As of current public disclosures, the drug is in the preclinical or early development phase, and specific details regarding its molecular target, mechanism of action, and specific cancer indications remain proprietary.

Beyond the preview

Go deeper on APZ102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APZ102.

Explore the full profile